


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (canceled)

Claim 2. (currently amended) A compound of the formula



wherein R_1 is independently selected from the group consisting of H; alkyl; substituted alkyl; alkoxy; halo; substituted alkoxy; hydroxy; trifluoralkyl; nitro; amino; alkylamino; cycloalkylamino; cyano; carboxy; cycloalkyl; phenyl; and substituted phenyl;

R_2 is independently selected from the group consisting of H; hydroxy; alkyl; substituted alkyl; halo; heterocycloalkyl; heteroaryl; phenyl; substituted phenyl; naphthyl and substituted naphthyl;

B_1 is hydrogen;

B_2 is hydrogen; or B_1 and B_2 are methylene and joined together to form a five or six membered ring;

Y is methylene or carbonyl;

~~Z is selected from the group consisting of aryl; substituted aryl; N-sulfonamido; N-(aryl)sulfonamido; substituted N-(aryl)sulfonamido; arylamido; substituted arylamido; arylureido; substituted arylureido; arylacetamido; substituted arylacetamido; (aryloxy)carbonylamino; substituted (aryloxy)carbonylamino; 2,3-dihydro-2-oxo-1H-~~

~~benzimidazol-1-yl; substituted 2,3-dihydro-2-oxo-1H-benzimidazol-1-yl; 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl; and substituted 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl;~~


L is selected from the group consisting of

C₁₋₈alkylene; C₂₋₁₀alkenylene; C₂₋₁₀alkynylene; C₃₋₇cycloalkylene;


C₃₋₇cycloalkylC₁₋₄alkylene;

arylC₁₋₄alkylene;


α-aminoC₄₋₇alkylene;




(N-methylene)piperidin-4-yl;




(N-methylene)piperazin-4-yl;




(N-methylene)pyrrolidin-3-yl;



(N-methylene)-4-acetyl-piperidin-4-yl;




and (N-methylene)piperidin-4,4-diyl;




Z is selected from the group consisting of


aryl;




N-sulfonamido;




N-(aryl)sulfonamido;




arylamido;




arylureido;




arylacetamido:




(aryloxy)carbonylamino;



2,3-dihydro-2-oxo-1H-benzimidazol-1-yl;



and 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl;



R₃ is independently selected from the group consisting of C₁₋₆ alkyl; substituted C₁₋₈ alkyl; cycloalkyl; substituted cycloalkyl; naphthyl; substituted naphthyl; heteroaryl; and substituted heteroaryl;

R₄ is independently selected from the group consisting of hydrogen; C₁₋₈ alkyl; C₁₋₈ alkoxy; substituted C₁₋₈ alkoxy; hydroxy; halogen; cyano; nitro; amino; C₁₋₈ alkylamino; and C₁₋₈ dialkylamino;

R₅ is independently selected from the group consisting of hydrogen;
C₁₋₈alkyl; C₁₋₈alkylcarbonyl; aroyl; carbamoyl; amidino; C₁₋₈alkyl;
C₁₋₈alkylaminocarbonyl; (arylamino)carbonyl; and arylC₁₋₈ alkylcarbonyl;

R₆ is independently selected from hydrogen and C₁₋₈alkyl;

n is 1-2;

m is 0-3;






p is 1-3; and

q is 1-3;

provided that when Z is aryl or heteroaryl, L is (N-methylene)piperazin-4-yl or (N-methylene)-4-acetylpiperidin-4-yl; and when Z is N-sulfonamido or N-(aryl)sulfonamido, L is α -aminoC₄₋₇alkylene, (N-methylene)piperidin-4-yl or (N-methylene)pyrrolidin-3-yl;


and enantiomers, diastereomers and pharmaceutically acceptable salts thereof.

Claim 3. (previously presented) A compound of claim 2 selected from the group consisting of:




and

Claim 4. (previously presented) A compound of claim 2 selected from the group consisting of:



Claim 5. (previously presented) A compound of claim 2 selected from the group consisting of:



and


Docket No. ORT-1588
Serial No. 10/071,483

Claim 6. (canceled)

Claim 7. (canceled)






Claim 8. (previously presented)
consisting of:

A compound of claim 2 selected from the group



and

Claim 9. (previously presented) A compound of claim 2 selected from the group consisting of:




and

Docket No. ORT-1588
Serial No. 10/071,483

Claim 10. (canceled)

Claim 11. (canceled)

Claim 12. (previously presented) A compound of claim 2 selected from the group consisting of:



and

Claim 13. (canceled)

Claim 14. (canceled)

Claim 15. (canceled)

Claim 16. (canceled)

Claim 17. (previously presented) A method of treating disorders and diseases associated with NPY receptor subtype 5 comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 2.

Claim 18. (previously presented) A pharmaceutical composition for the treatment of diseases or disorders associated with the NPY Y5 receptor subtype comprising a therapeutically effective amount of a compound of claim 2 and a pharmaceutically acceptable carrier.

Claim 19. (previously presented) A pharmaceutical composition according to claim 18 for the treatment of disorders or disease states caused by eating disorders, obesity, bulimia nervosa, diabetes, memory loss, epileptic seizures, migraine, sleep disturbances, pain, sexual/reproductive disorders, depression and anxiety.